Johnson & Johnson
JNJ
Company Profile
Business description
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.
Contact
One Johnson & Johnson Plaza
New BrunswickNJ08933
USAT: +1 732 524-0400
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
140,800
Johnson & Johnson News & Analysis
markets
US stock market outlook: Where to find value after April’s rally
Our reallocation strategy is working as intended. Opportunities remain in AI, tech, and small-caps.
personal-finance
Howard Marks warns of stock market froth
The renowned investor has penned his first investor letter for 2025 and it’s a ripper. He runs through what bubbles are, which ones he’s experienced, and whether today’s markets qualify as the third major bubble of this century.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,165.40 | 39.10 | -0.42% |
| CAC 40 | 8,368.91 | 7.55 | 0.09% |
| DAX 40 | 26,749.95 | 21.93 | -0.08% |
| Dow JONES (US) | 52,347.55 | 50.46 | 0.10% |
| FTSE 100 | 10,902.56 | 39.47 | 0.36% |
| HKSE | 23,767.28 | 129.68 | 0.55% |
| NASDAQ | 25,136.27 | 229.82 | -0.91% |
| Nikkei 225 | 59,676.00 | 1,466.35 | -2.40% |
| NZX 50 Index | 14,303.77 | 130.09 | 0.92% |
| S&P 500 | 7,561.67 | 30.73 | -0.40% |
| S&P/ASX 200 | 9,044.70 | 37.50 | -0.41% |
| SSE Composite Index | 3,595.25 | 39.10 | -1.08% |